Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme

Hdl Handle:
http://hdl.handle.net/10144/618786
Title:
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
Authors:
Kimutai, R; Musa, AM; Njoroge, S; Omollo, R; Alves, F; Hailu, A; Khalil, EAG; Diro, E; Soipei, P; Musa, B; Salman, K; Ritmeijer, K; Chappuis, F; Rashid, J; Mohammed, R; Jameneh, A; Makonnen, E; Olobo, J; Okello, L; Sagaki, P; Strub, N; Ellis, S; Alvar, J; Balasegaram, M; Alirol, E; Wasunna, M
Journal:
Clinical Drug Investigation
Abstract:
In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.
Publisher:
Springer Link
Issue Date:
9-Jan-2017
URI:
http://hdl.handle.net/10144/618786
DOI:
10.1007/s40261-016-0481-0
PubMed ID:
28066878
Submitted date:
2017-01-18
Language:
en
ISSN:
1179-1918
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorKimutai, Ren
dc.contributor.authorMusa, AMen
dc.contributor.authorNjoroge, Sen
dc.contributor.authorOmollo, Ren
dc.contributor.authorAlves, Fen
dc.contributor.authorHailu, Aen
dc.contributor.authorKhalil, EAGen
dc.contributor.authorDiro, Een
dc.contributor.authorSoipei, Pen
dc.contributor.authorMusa, Ben
dc.contributor.authorSalman, Ken
dc.contributor.authorRitmeijer, Ken
dc.contributor.authorChappuis, Fen
dc.contributor.authorRashid, Jen
dc.contributor.authorMohammed, Ren
dc.contributor.authorJameneh, Aen
dc.contributor.authorMakonnen, Een
dc.contributor.authorOlobo, Jen
dc.contributor.authorOkello, Len
dc.contributor.authorSagaki, Pen
dc.contributor.authorStrub, Nen
dc.contributor.authorEllis, Sen
dc.contributor.authorAlvar, Jen
dc.contributor.authorBalasegaram, Men
dc.contributor.authorAlirol, Een
dc.contributor.authorWasunna, Men
dc.date.accessioned2017-02-17T13:02:45Z-
dc.date.available2017-02-17T13:02:45Z-
dc.date.issued2017-01-09-
dc.date.submitted2017-01-18-
dc.identifier.citationSafety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. 2017 Clin Drug Investigen
dc.identifier.issn1179-1918-
dc.identifier.pmid28066878-
dc.identifier.doi10.1007/s40261-016-0481-0-
dc.identifier.urihttp://hdl.handle.net/10144/618786-
dc.description.abstractIn 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.en
dc.language.isoenen
dc.publisherSpringer Linken
dc.rightsArchived with thanks to Clinical Drug Investigationen
dc.titleSafety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programmeen
dc.identifier.journalClinical Drug Investigationen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.